Alimera Sciences Company Profile and Strategy

Alimera Sciences is a biopharmaceutical company that focuses on developing and commercializing ophthalmic products. Founded in 2009, the company has a strong presence in the US market.

Alimera Sciences has a unique approach to developing ophthalmic treatments, with a focus on innovative products that address unmet medical needs. The company's strategy is centered around commercializing existing products and developing new ones through partnerships and collaborations.

One of the company's most notable products is Iluvien, a sustained-release corticosteroid implant for the treatment of diabetic macular edema. Iluvien has been a key driver of the company's growth and success.

Alimera Sciences' operations are focused on developing and commercializing ophthalmic pharmaceuticals.

The company has a partnership with Pfizer to develop and commercialize Iluvien, a sustained-release intravitreal implant for the treatment of diabetic macular edema.

Alimera Sciences has a commercial presence in several countries, including the United States, Europe, and Asia.

The United States (U.S.) was the largest market for Alimera Sciences, Inc. with sales of $56.71 million in 2023.

In contrast, international sales were significantly lower, reaching $24.04 million in 2023.

The U.S. market showed a significant increase in sales from 2022 to 2023, with a growth of $22.51 million.

International sales, on the other hand, declined by $5.89 million from 2022 to 2023.

Here's a breakdown of the sales figures for the U.S. and international markets over the years:

Alimera has a second NIU therapy in its portfolio. This is YUTIQ, an FDA-approved therapeutic acquired from EyePoint Pharmaceuticals in May 2023.

YUTIQ is indicated for treating chronic non-infectious uveitis (NIU) impacting the posterior segment of the eye.

Both ILUVIEN and YUTIQ release fluocinolone acetonide for up to 36 months.

Expand your knowledge: Cassa Centrale Banca - Credito Cooperativo Italiano

Alimera Sciences has a strong leadership team in place. The company's CEO, Richard Eiswirth, has been at the helm since January 1, 2019, bringing over 20 years of experience to the role.

The Executive Committee includes several key members, each with their own area of expertise. David Holland has been leading the Sales & Marketing team since May 5, 2010, and has a wealth of knowledge in his field.

The company's Chief Operating Officer, Jason Werner, joined the team on October 1, 2023, bringing a fresh perspective and set of skills to the role. Elliot Maltz, the Director of Finance/CFO, took over in January 2024, and is responsible for overseeing the company's financial operations.

Here's a brief overview of the company's leadership team:

At Alimera Sciences, commitment to excellence is a core value that drives everything they do. The company's focus on retinal health through cutting-edge technology is a testament to this dedication.

Their patient-centric approach means they prioritize the needs of those they serve, making a real difference in people's lives. This approach is evident in their work on non-infectious uveitis and conditions secondary to diabetic complications.

Alimera's balanced approach between clinical research and market application is a key factor in their success, demonstrating a commitment to delivering advanced ophthalmic therapies. This commitment to excellence is what sets them apart in the pharmaceutical industry.

The Executive Committee plays a crucial role in shaping the direction of Alimera Sciences, Inc. David Holland has been leading the Sales & Marketing efforts since 2010, bringing a wealth of experience to the table.

Richard Eiswirth has been at the helm as CEO since January 2019, overseeing the company's overall strategy and vision. He's been with the company for over 4 years now.

Elliot Maltz joined the team in 2024 as the Director of Finance/CFO, bringing a fresh perspective to the company's financial management. Jason Werner took on the role of Chief Operating Officer in October 2023, focusing on operational efficiency and effectiveness.

The team is rounded out by Laura Cegala, who has been handling Human Resources tasks, although her exact tenure and age are not publicly disclosed.

Here's a quick rundown of the Executive Committee members:

The Board of Directors Composition is a crucial aspect of a company's leadership and governance. Charles Myers serves as the Chairman of Alimera Sciences, Inc., a position he has held since January 1, 2019.

Charles Myers is 71 years old, bringing a wealth of experience to the role.

Additional reading: Charles Schwab Corporation

Alimera Sciences has multiple legal entities associated with it.

The company was incorporated in the United States on October 19, 2003, as Alimera Sciences Inc. with a CIN of 1267602.

Alimera Sciences Inc has reported a revenue of $80.8M as of December 31, 2023.

There is another legal entity associated with the company, ALIMERA SCIENCES, INC, with a CIN of 200028718, which was incorporated on December 31, 2002.

This entity had 79 employees as of December 31, 2022.

See what others are reading: Countrywide Legal Indemnities

Alimera Sciences is at the forefront of innovation in the ophthalmology sector, leveraging advanced sustained release technologies to tackle diseases affecting the back of the eye.

The company's CONTINUOUS MICRODOSING platform enables the delivery of sub-microgram levels of fluocinolone acetonide over extended durations.

This precision drug delivery approach reduces injection frequency and aims to maintain patient vision longer, addressing a critical unmet need in the industry.

By streamlining treatment and improving patient outcomes, Alimera Sciences is revolutionizing the way we approach eye health.

Alimera Sciences operates in a highly specialized niche, focusing on retinal diseases and serving a global market. Its expertise in managing complex retinal conditions has earned it a reputation among retina specialists.

The company's clear segmentation of its portfolio underscores its focus on treating both early- and late-stage retinal diseases. In the United States, Alimera addresses conditions such as diabetic macular edema and uveitis, while in Europe, it caters to patients with limited treatment options through its London-based subsidiary.

Alimera Sciences has a strong presence in the market, but it's not alone. Here are some of its top competitors:

These competitors have varying levels of funding and expertise, but all are focused on developing treatments for retinal and eye diseases.

Alimera Sciences operates in a highly specialized niche, focusing on treating both early- and late-stage retinal diseases. This specialization has earned the company a strong reputation among retina specialists.

The company's portfolio is designed to address specific conditions, such as diabetic macular edema and uveitis. Its various approved indications in the United States demonstrate this focus.

Alimera Sciences serves a global market with a dual focus. In the US, it addresses conditions like diabetic macular edema and uveitis, while in Europe, it caters to patients with limited treatment options through its London-based subsidiary.

This clear segmentation underscores Alimera's expertise in managing complex retinal conditions.

Discover more: Focus Financial Partners

Alimera Sciences has some notable competitors in the field of ophthalmology. Annexon, a San Francisco-based company, is the overall leader with a Tracxn score of 69/100 and total funding of $256M.

One of the key competitors is Aldeyra, a Lexington-based company that has developed drugs for the treatment of immune-mediated diseases. They have a Tracxn score of 63/100 and total funding of $4.79M.

The table below shows the top 5 competitors of Alimera Sciences:

These companies are all working on innovative solutions to treat various eye diseases, and Alimera Sciences is likely to face stiff competition in the market.

Ani Pharmaceuticals Acquires Alimera Sciences for $381 million. The deal values Alimera at approximately $381 million in upfront consideration.

The acquisition is expected to close late in the third quarter of 2024, and ANI Pharmaceuticals will acquire Alimera Sciences for $5.50 per share in cash at closing. Alimera's two commercial products, ILUVIEN and YUTIQ, will be integrated into ANI's Rare Disease business.

Take a look at this: Gov. Hochul Invests $10 Million in Science of Reading Training

ILUVIEN is indicated for diabetic macular edema (DME) in the U.S., Europe, and the Middle East, as well as for chronic non-infectious uveitis affecting the posterior segment (NIU-PS) in Europe and the Middle East. YUTIQ is available in the U.S. only and is indicated for the treatment of chronic NIU-PS.

The acquisition is expected to drive substantial shareholder value creation through high single-digit to low double-digit accretion in adjusted Non-GAAP EPS in 2025.

Readers also liked: Pacific East Asia Cargo Airlines

Alimera Sciences has a significant funding history, with a total of $66.8M raised over 9 rounds. Its first funding round took place on November 30, 2005.

The company has 11 institutional investors, including well-known names like Venrock, Polaris Partners, and Scale Venture Partners.

Alimera Sciences has received funding in various forms, including conventional debt and post-IPO funding rounds. The company's post-IPO funding rounds have been quite substantial, with $81M raised in May 2023 and $20M raised in October 2019.

Here's a breakdown of Alimera Sciences' funding rounds:

Alimera Sciences' funding rounds have been used to support its growth and development.

Alimera Sciences is dedicated to advancing clinical knowledge in ophthalmology through robust research and development efforts.

The company pursues evidence-based strategies by engaging with networks such as the DRCR Retina Network.

By participating in clinical trials and scientific programs, Alimera aims to validate the efficacy and safety of its ophthalmic products.

Through its research, Alimera aims to address complications like radiation retinopathy.

The company's commitment to advancing clinical knowledge is reflected in its participation in prominent conferences.

Suggestion: Cambridge Investment Research

Alimera Sciences has international operations that enable it to reach diverse markets. This allows the company to integrate clinical insights and patient needs into its global strategy.

The company's operational model supports a wide range of therapeutic indications. This adaptability is crucial for success in a competitive industry where regulatory landscapes can be complex.

Alimera Sciences' expertise in sustained drug delivery bolsters its clinical credibility. This expertise also positions the company as a valuable resource for physicians and patients seeking improved retinal health outcomes.

The company's steadiness in a competitive industry is reinforced by its operational model. This model ensures that the company can respond effectively to changing market conditions.